 "Zydus buys Zoetis' select brands and Haridwar plant")
In a major strategic move to give a boost to its animal health business, Zydus Group has acquired select brands and the manufacturing operations in Haridwar of Zoetis, a global animal health company. The acquisition will help Zydus expand its animal health business in India and gain access to manufacturing operations which have also been catering to global markets. The financial details of the deal remain undisclosed.
“We believe that this strategic acquisition will strengthen our portfolio of brands and add new dimensions to our growth in the animal health business. We see this as an opportunity to catapult our business to higher levels of excellence,” commented Pankaj Patel, chairman and managing director, Zydus Cadila.
As a result of this acquisition, Zydus gains access to a wide range of nutrition as well as therapeutic products which have strong brand equity and a combined turnover of Rs 171 crore. A major boost to Zydus’ portfolio would be the addition of livestock farmcare products which are well accepted in the market. Zydus’ access to the WHO GMP approved manufacturing facility is expected to boost its exports and institutional business. The plant spread over 10,000 sq m manufactures tablets, liquid orals and injectables.
With a strong presence in the livestock and poultry segments, Zydus Animal Health is India’s leading animal healthcare player and a market leader in various therapeutic segments which include antibacterials, NSAIDs, antimastitis, tonics and poultry vaccines among others in India.
“We believe that this strategic acquisition will strengthen our portfolio of brands and add new dimensions to our growth in the animal health business. We see this as an opportunity to catapult our business to higher levels of excellence,” commented Pankaj Patel, chairman and managing director, Zydus Cadila.
As a result of this acquisition, Zydus gains access to a wide range of nutrition as well as therapeutic products which have strong brand equity and a combined turnover of Rs 171 crore. A major boost to Zydus’ portfolio would be the addition of livestock farmcare products which are well accepted in the market. Zydus’ access to the WHO GMP approved manufacturing facility is expected to boost its exports and institutional business. The plant spread over 10,000 sq m manufactures tablets, liquid orals and injectables.
With a strong presence in the livestock and poultry segments, Zydus Animal Health is India’s leading animal healthcare player and a market leader in various therapeutic segments which include antibacterials, NSAIDs, antimastitis, tonics and poultry vaccines among others in India.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%